Chinese pharma maker of generic drugs and IV infusions, with a biotech arm developing antibody-drug conjugates licensed to Merck.
Chinese pharma maker of generic drugs and IV infusions, with a biotech arm developing antibody-drug conjugates licensed to Merck.
Earns most of its income from selling large-volume IV infusions, such as saline and glucose bags, and generics to hospitals, a volume business squeezed by government bulk-buying tenders. Its separately listed subsidiary, Kelun-Biotech, brings licensing and milestone income from Merck for antibody-drug conjugates, drugs that carry a toxin straight to tumor cells.
In one line: A generics manufacturer with a Seagen-like ADC biotech unit.
Moat: narrow (IP / patents, scale). Large generics/infusion base funds an ADC pipeline validated by a major Merck licensing deal.
Headquarters: Chengdu, China · Founded: 1996 · Employees: 20,127
Size Sichuan Kelun Pharmaceutical (002422.SZ) is a China Health Care company (Biotechnology) with a market value of $10.1B, the 234th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥42.29 on 18 Nov 2026.
Performance Over six months the shares gained 34.8%, against +23.0% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 0.3% over the last twelve months (peer median +32.0%); the operating margin is 9.4% (peer median 9.9%).
Valuation It trades at 35.6× forward earnings against a peer median of 28.0× (5th most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥18.3B | CN¥18.4B | CN¥21.6B | CN¥21.3B | CN¥18.9B |
| Revenue growth | — | -15% | +2% | +13% | — |
| Gross profit | CN¥9.60B | CN¥8.40B | CN¥10.8B | CN¥10.8B | CN¥9.57B |
| EBITDA | n/a | CN¥3.43B | CN¥5.14B | CN¥4.54B | CN¥3.39B |
| Net income | CN¥1.97B | CN¥1.70B | CN¥2.94B | CN¥2.46B | CN¥1.71B |
| Free cash flow | CN¥2.49B | CN¥1.19B | CN¥3.02B | CN¥3.70B | CN¥2.34B |
| Capital expenditure | CN¥1.40B | CN¥1.62B | CN¥1.68B | CN¥1.77B | CN¥897M |
| Total debt | CN¥4.33B | CN¥4.36B | CN¥4.42B | CN¥7.56B | CN¥11.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical 002422.SZ | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
| Sbp 1177.HK | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002422.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.1% | -5.4% | 10th highest of 21 |
| 6-month return | +34.8% | +23.0% | 8th highest of 21 |
| Distance from 52-week high | -19.9% | -26.2% | 10th highest of 21 |
| Revenue growth (TTM) | +0.3% | +32.0% | 3rd lowest of 17 |
| Operating margin | 9.4% | 9.9% | 9th highest of 17 |
| Forward P/E | 35.6× | 28.0× | 5th most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 6.2% | 18.9% | 4th least demanding of 11 |
| Growth delivered (Del g) | +2.3% | +18.2% | 2nd lowest of 11 |
| Hurdle (Req g minus delivered) | +3.8 pp | -7.3 pp | 5th most demanding of 11 |
| ROIC minus cost of capital | +1.6 pp | -3.6 pp | 6th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% | +2.3% |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | n/a | n/a | n/a |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 9.5× | -0.3% | +39.2% |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 36.3× | 13.1% | +26.0% |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% | +5.5% |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 42.0× | 24.6% | +38.5% |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 294.1× | 36.9% | +19.8% |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% | +12.0% |
| Cspc Pharma 1093.HK | Hong Kong | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% | +0.1% |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% | +7.6% |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | n/a | 47.2% | +16.6% |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | n/a | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 77.1× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| BridgeBio Pharma BBIO | United States | $15.2B | +14% | +167% | -37% | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | United States | $16.5B | +5% | +38% | 25% | 18.0× | -1.5% | +22.3% |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | n/a | n/a | n/a |